Hydroxyurea Composition for Severe Chronic Anemia in Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective treatment for sustained improvement of severe chronic anemia in patients with sickle cell disease who are not already undergoing treatment with hydroxyurea or do not have vaso-occlusive crisis.
Innovation Solution
A pharmaceutical composition comprising hydroxyurea is used to treat severe chronic anemia in patients with sickle cell disease, increasing the total hemoglobin level by administering doses ranging from 10 to 40 mg/kg/day, typically in the form of tablets or liquid formulations, to enhance hemoglobin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hydroxyurea is administered to treat severe chronic anemia in sickle cell patients, then hemoglobin levels increase, but myelosuppression may occur
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage regimen of hydroxyurea (10-40 mg/kg/day) and monitoring hemoglobin levels to optimize therapeutic effect while avoiding myelosuppression. The treatment modifies the concentration parameter of hemoglobin from baseline ≤7.5 g/dl to therapeutic levels >7.5 g/dl through controlled administration of the active substance.
2Object-affected harmful factors
If no treatment is administered to severe chronic anemia, then myelosuppression is avoided, but hemoglobin levels remain critically low
Solution Approach 1:
The patent employs self-service principles by enabling patients to self-monitor hemoglobin levels and adjust treatment adherence, combined with regular clinical monitoring. This approach allows the treatment system to automatically identify patients achieving therapeutic thresholds (>7.5 g/dl) while maintaining safety margins against myelosuppression through patient-driven compliance and physician oversight.
Data Source
AI summary
The invention relates to the method of use of a pharmaceutical composition containing hydroxyurea, for the treatment of severe chronic anemia in a patient suffering from sickle cell anemia not already undergoing treatment with hydroxyurea and not suffering a vaso-occlusive crisis.